Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 12, 2019. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| April 11, 2019 | Ordinary Shares (25p) | £15.7335 | 1,560 shares | London Stock Exchange |
Transaction Breakdown:
- Mrs V A Whyte (Company Secretary): Acquired 35 shares.
- Mr I W Whyte (PCA of Company Secretary): Acquired 880 shares.
- Mrs D Connor (PCA of President, Global Vaccines): Acquired 645 shares.
Material Changes
The filing does not report material changes to the company's financial position or operations. The reported activity consists solely of share acquisitions resulting from the re-investment of dividends paid to shareholders on April 11, 2019.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with the Securities Exchange Act of 1934.
Investor Verification Points
- Verify that the share acquisitions were executed strictly through a dividend re-investment plan as stated.
- Confirm the share price of £15.7335 aligns with the market price on the London Stock Exchange for April 11, 2019.
- Ensure the total volume of 1,560 shares matches the sum of individual transactions reported.